一分钟看懂
这是一项关于头颈部肿瘤的II 期研究，登记的药物或干预包括Engineered Mitochondrial Vaccine (IMP3-Mito)；Immune checkpoint inhibitor (ICI)，当前状态为招募中。登记地点显示中国成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Engineered Mitochondrial Vaccine (IMP3-Mito)；Immune checkpoint inhibitor (ICI) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West China Hospital, Sichuan University · 成都
公开的入选条件
- 1. Aged ≥ 18 years, both genders eligible.
- 2. Pathologically confirmed head and neck squamous cell carcinoma (HNSCC) meeting the following criteria:
- 1. Clinical stage II-IVB according to the AJCC 8th Edition (nasopharyngeal carcinoma is excluded);
- 2. Positive expression of IMP3 protein;
- 3. Clinically resectable as determined by a Multidisciplinary Team (MDT);
- 4. Subjects must be willing and able to undergo radical surgery.
- 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- 4. Adequate organ and bone marrow function, defined as:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07572864；登记信息更新于 2026-09-17。